{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:26:38Z","timestamp":1787981198573,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Huntington\u2019s disease (HD) is a devastating and fatal neurodegenerative disorder that leads to progressive disability, and over time to total dependence. The economic impact of HD on patients living in developing countries like Peru is still unknown. This study aims to estimate the economic burden by estimating direct and indirect costs of Huntington\u2019s disease in Peru, as well as the proportion of direct costs borne by patients and their families.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Disease-cost cross-sectional study where 97 participants and their primary caregivers were interviewed using a common questionnaire. Prevalence and human capital approaches were used to estimate direct and indirect costs, respectively.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The average annual cost of HD reached USD 8120 per patient in 2015. Direct non-healthcare costs represented 78.3% of total cost, indirect costs 14.4% and direct healthcare costs the remaining 7.3%. The mean cost of HD increased with the degree of patient dependency: from USD 6572 for Barthel 4 &amp; 5 (slight dependency and total independency, respectively) to USD 23,251 for Barthel 1 (total dependency). Direct costs were primarily financed by patients and their families.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The estimated annual cost of HD for Peruvian society reached USD 1.2 million in 2015. The cost impact of HD on patients and their families is very high, becoming catastrophic for most dependent patients, and thus making it essential to prioritize full coverage by the State.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12913-019-4806-6","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T20:02:17Z","timestamp":1577736137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Economic burden of Huntington\u2019s disease in Peru"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6132-2239","authenticated-orcid":false,"given":"Gustavo","family":"Silva-Paredes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Urbanos-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Inca-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Rabinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario R.","family":"Cornejo-Olivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"4806_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83\u201398.","journal-title":"Lancet Neurol"},{"key":"4806_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1055\/s-2007-971176","volume":"27","author":"FO Walker","year":"2007","unstructured":"Walker FO. Huntington's disease. Semin Neurol. 2007;27:143\u201350.","journal-title":"Semin Neurol"},{"key":"4806_CR3","doi-asserted-by":"publisher","first-page":"c3109","DOI":"10.1136\/bmj.c3109","volume":"340","author":"MJ Novak","year":"2010","unstructured":"Novak MJ, Tabrizi SJ. Huntington's disease. BMJ. 2010;340:c3109.","journal-title":"BMJ"},{"key":"4806_CR4","doi-asserted-by":"publisher","first-page":"RRN1206","DOI":"10.1371\/currents.RRN1206","volume":"3","author":"M Busse","year":"2011","unstructured":"Busse M, Al-Madfai DH, Kenkre J, Landwehrmeyer GB, Bentivoglio A, Rosser A. European Huntington's Disease NetworkUtilisation of Healthcare and Associated Services in Huntington's disease: a data mining study. PLoS Curr. 2011;3:RRN1206. https:\/\/doi.org\/10.1371\/currents.RRN1206.","journal-title":"PLoS Curr"},{"key":"4806_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","volume":"8","author":"JM van der Burg","year":"2009","unstructured":"van der Burg JM, Bjorkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009;8:765\u201374.","journal-title":"Lancet Neurol"},{"key":"4806_CR6","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disorders. 2012;27:1083\u201391.","journal-title":"Mov Disorders"},{"key":"4806_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"MD Rawlins","year":"2016","unstructured":"Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJW, Smeeth L. The Prevalence of Huntington\u2019s Disease. Neuroepidemiology. 2016;46:144\u201353. https:\/\/doi.org\/10.1159\/000443738.","journal-title":"Neuroepidemiology"},{"key":"4806_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1474-4422(13)70006-1","volume":"12","author":"A Burton","year":"2013","unstructured":"Burton A. Hope, humanity, and Huntington's disease in Latin America. Lancet Neurol. 2013;12:133\u20134.","journal-title":"Lancet Neurol"},{"key":"4806_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.20453\/rnp.v79i4.2977","volume":"79","author":"NR Espinoza-Su\u00e1rez","year":"2016","unstructured":"Espinoza-Su\u00e1rez NR, Palacios-Garc\u00eda J, Morante-Osores MR. Cuidados paliativos en la enfermedad de Huntington: perspectivas desde la atenci\u00f3n primaria de salud. Rev Neuro-Psiquiatr\u00eda. 2016;79:230\u20138.","journal-title":"Rev Neuro-Psiquiatr\u00eda"},{"key":"4806_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3233\/JHD-140119","volume":"4","author":"MR Cornejo-Olivas","year":"2015","unstructured":"Cornejo-Olivas MR, Inca-Martinez MA, Espinoza-Huertas K, Veliz-Otani D, Velit-Salazar MR, Marca V, Ortega O, Cornejo-Herrera IF, Lindo-Samanamud S, Mora-Alferez P, Mazzetti P. Clinical and molecular features of late onset Huntington disease in a Peruvian cohort. J Huntington's Dis. 2015;4:99\u2013105.","journal-title":"J Huntington's Dis"},{"key":"4806_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s12687-015-0239-z","volume":"6","author":"M Cornejo-Olivas","year":"2015","unstructured":"Cornejo-Olivas M, Espinoza-Huertas K, Velit-Salazar MR, Veliz-Otani D, Tirado-Hurtado I, Inca-Martinez M, Silva-Paredes G, Milla-Neyra K, Marca V, Ortega O, Mazzetti P. Neurogenetics in Peru: clinical, scientific and ethical perspectives. J Community Genetics. 2015;6:251\u20137.","journal-title":"J Community Genetics"},{"key":"4806_CR12","first-page":"393","volume":"31","author":"A Hernandez-Vasquez","year":"2014","unstructured":"Hernandez-Vasquez A, Rubilar-Gonzalez J, Pisfil-Benites N. Financing for rare or orphan diseases: a thing to do. Rev Peru. Med Exp Salud P\u00fablica. 2014;31:393.","journal-title":"Rev Peru. Med Exp Salud P\u00fablica"},{"key":"4806_CR13","first-page":"808","volume":"31","author":"A Oyola-Garc\u00eda","year":"2014","unstructured":"Oyola-Garc\u00eda A, Lituma-Aguirre D, Honorio-Morales H. Comisi\u00f3n Sectorial Enfermedades Raras, Financing rare or orphan diseases. Rev Peru Med Exp Salud P\u00fablica. 2014;31:808\u20139.","journal-title":"Rev Peru Med Exp Salud P\u00fablica"},{"key":"4806_CR14","doi-asserted-by":"publisher","first-page":"546","DOI":"10.17843\/rpmesp.2016.333.2338","volume":"33","author":"A Velasquez","year":"2016","unstructured":"Velasquez A, Suarez D, Nepo-Linares E. Health sector reform in Peru: law, governance, universal coverage, and responses to health risks. Rev Peru Med Exp Salud P\u00fablica. 2016;33:546\u201355.","journal-title":"Rev Peru Med Exp Salud P\u00fablica"},{"key":"4806_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.17843\/rpmesp.2015.323.1675","volume":"32","author":"P Ypanaque-Luyo","year":"2015","unstructured":"Ypanaque-Luyo P, Martins M. Utilization of outpatient health services in the Peruvian population. Rev Peru Med Exp Salud P\u00fablica. 2015;32:464\u201370.","journal-title":"Rev Peru Med Exp Salud P\u00fablica"},{"issue":"Suppl 2","key":"4806_CR16","first-page":"s243","volume":"53","author":"JE Alcalde-Rabanal","year":"2011","unstructured":"Alcalde-Rabanal JE, Lazo-Gonzalez O, Nigenda G. The health system of Peru. Salud P\u00fablica Mex. 2011;53(Suppl 2):s243\u201354.","journal-title":"Salud P\u00fablica Mex"},{"key":"4806_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3111\/13696998.2013.818545","volume":"16","author":"V Divino","year":"2013","unstructured":"Divino V, Dekoven M, Warner JH, Giuliano J, Anderson KE, Langbehn D, Lee WC. The direct medical costs of Huntington's disease by stage. A retrospective commercial and Medicaid claims data analysis. J. Med. Econ. 2013;16:1043\u201350.","journal-title":"J. Med. Econ"},{"key":"4806_CR18","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/ene.13107","volume":"23","author":"C Jones","year":"2016","unstructured":"Jones C, Busse M, Quinn L, Dawes H, Drew C, Kelson M, et al. The societal cost of Huntington\u2019s disease: are we underestimating the burden? Eur J Neurol. 2016;23:1588\u201390.","journal-title":"Eur J Neurol"},{"key":"4806_CR19","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J. 1965;14:61\u20135.","journal-title":"Md State Med J"},{"key":"4806_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","volume":"20","author":"J Changik","year":"2014","unstructured":"Changik J. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327\u201337.","journal-title":"Clin Mol Hepatol"},{"key":"4806_CR21","unstructured":"Instituto Nacional de Ciencias Neurol\u00f3gicas, Tarifario, Retrieved from: http:\/\/www.incn.gob.pe\/index.php\/53-atencion\/51-tarifas."},{"key":"4806_CR22","unstructured":"Direcci\u00f3n General de Medicamentos, Insumos y Drogas, M\u00f3dulo de consulta de precios, Retrieved from: http:\/\/observatorio.digemid.minsa.gob.pe\/."},{"key":"4806_CR23","volume-title":"Los costes socioecon\u00f3micos y la calidad de Vida relacionada con la salud en pacientes con enfermedades raras en Espa\u00f1a, Proyecto de IMSERSO 167\/10","author":"J L\u00f3pez Bastida","year":"2012","unstructured":"L\u00f3pez Bastida J, Lineryiv\u00e1 R, Serrano P, Hens M, Posada de la Paz M, Oliva J. Los costes socioecon\u00f3micos y la calidad de Vida relacionada con la salud en pacientes con enfermedades raras en Espa\u00f1a, Proyecto de IMSERSO 167\/10. Servicios Sociales e Igualdad: Ministerio de Sanidad; 2012. Retrieved from: http:\/\/www.imserso.es\/InterPresent2\/groups\/imserso\/documents\/binario\/010_167idi.pdf"},{"key":"4806_CR24","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40273-013-0104-z","volume":"31","author":"RJ Hoefman","year":"2013","unstructured":"Hoefman RJ, van Exel J, Brouwer W. How to include informal care in economic evaluations. Pharmacoeconomics. 2013;31:1105\u201319.","journal-title":"Pharmacoeconomics"},{"key":"4806_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40273-016-0468-y","volume":"35","author":"J Oliva-Moreno","year":"2017","unstructured":"Oliva-Moreno J, Trapero-Bertran M, Pe\u00f1a-Longobardo LM, del Pozo-Rubio R. The valuation of informal Care in Cost-of-Illness Studies: a systematic review. Pharmacoeconomics. 2017;35:331\u201345.","journal-title":"Pharmacoeconomics"},{"key":"4806_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-199813010-00001","volume":"13","author":"B Liljas","year":"1998","unstructured":"Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998;13:1\u20137.","journal-title":"Pharmacoeconomics"},{"key":"4806_CR27","unstructured":"Instituto Nacional de Estad\u00edstica e Inform\u00e1tica (INEI), Encuesta Nacional de Hogares sobre Condiciones de Vida y Pobreza 2015, Retrieved from: https:\/\/webinei.inei.gob.pe\/anda_inei\/index.php\/catalog\/276"},{"key":"4806_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/cge.12641","volume":"89","author":"RM Castilhos","year":"2016","unstructured":"Castilhos RM, Augustin MC, Santos JA, Perandones C, Saraiva-Pereira ML, Jardim LB, Rede N. Genetic aspects of Huntington's disease in Latin America. A systematic review. Clin. Genet. 2016;89:295\u2013303.","journal-title":"Clin. Genet"},{"key":"4806_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-801893-4.00003-1","volume":"144","author":"C Kay","year":"2017","unstructured":"Kay C, Hayden MR, Leavitt BR. Epidemiology of Huntington disease. Handb Clin Neurol. 2017;144:31\u201346.","journal-title":"Handb Clin Neurol"},{"key":"4806_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.17843\/rpmesp.2015.324.1773","volume":"32","author":"P Mazzetti","year":"2015","unstructured":"Mazzetti P, Inca-Martinez M, Tirado-Hurtado I, Milla-Neyra K, Silva-Paredes G, Vishnevetsky A, Cornejo-Olivas M. Neurogenetics in Peru, example of translational research. Rev Peru Med Exp Salud P\u00fablica. 2015;32:787\u201393.","journal-title":"Rev Peru Med Exp Salud P\u00fablica"},{"key":"4806_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.21083\/surg.v1i1.338","volume":"1","author":"E Smolina","year":"2007","unstructured":"Smolina E. Psychosocial impact of Huntington\u2019s disease on families and spouses from the perspective of the family systems theory. SURG Journal. 2007;1:51\u201362.","journal-title":"SURG Journal"},{"key":"4806_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4321\/S1137-66272012000200011","volume":"35","author":"M Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez M, Grau C, Trigo P. Impacto de la enfermedad de Huntington en la familia. Anales del Sistema Sanitario de Navarra. 2012;35:295\u2013307.","journal-title":"Anales del Sistema Sanitario de Navarra"},{"key":"4806_CR33","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/mds.26012","volume":"29","author":"CA Ross","year":"2014","unstructured":"Ross CA, Pantelyat A, Kogan J, Brandt J. Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction. Mov Disord. 2014;29:1351\u20138.","journal-title":"Mov Disord"},{"key":"4806_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3233\/JAD-2010-1258","volume":"19","author":"A Coduras","year":"2010","unstructured":"Coduras A, Rabasa I, Frank A, Bermejo-Pareja F, Lopez-Pousa S, Lopez-Arrieta JM, Del Llano J, Leon T, Rejas J. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study. J Alzheimers Dis. 2010;19:601\u201315.","journal-title":"J Alzheimers Dis"},{"key":"4806_CR35","unstructured":"World Health Organization. Global Health Expenditure Database. Retrieved from: https:\/\/apps.who.int\/nha\/database\/ViewData\/Indicators\/en"},{"key":"4806_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3233\/JHD-160192","volume":"5","author":"JC Frich","year":"2016","unstructured":"Frich JC, Rae D, Roxburgh R, Miedzybrodzka ZH, Edmondson M, Pope EB, Goodman L, Haddad MS, Giuliano J, Nelson EC, Guttman M, Nance M. Health care delivery practices in Huntington's disease specialty clinics: an international survey. J Huntington's Dis. 2016;5:207\u201313.","journal-title":"J Huntington's Dis"},{"key":"4806_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/B978-0-12-801893-4.00014-6","volume":"144","author":"MC Edmondson","year":"2017","unstructured":"Edmondson MC, Goodman L. Contemporary health care for Huntington disease. Handb Clin Neurol. 2017;144:167\u201378.","journal-title":"Handb Clin Neurol"},{"key":"4806_CR38","unstructured":"World Health Organization, Designing Health Financing Systems to Reduce Catastrophic Health Expenditure, Technical Briefs for Policy Makers, Number 2 (2005), Retrieved from: https:\/\/www.who.int\/health_financing\/documents\/pb_e_05_2-cata_sys.pdf"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-019-4806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-019-4806-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-019-4806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:18:53Z","timestamp":1609201133000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-019-4806-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4806"],"URL":"https:\/\/doi.org\/10.1186\/s12913-019-4806-6","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"17 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GSP, RUG, DR have no competing interests. MCO, MIM are local researchers for the Enroll HD study-site Peru.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1017"}}